A multicentre, phase II randomised controlled trial evaluating cabazitaxel versus docetaxel rechallenge for the treatment of metastatic Castrate Refractory Prostate Cancer, previously treated with docetaxel at inception of primary hormone therapy

Trial Profile

A multicentre, phase II randomised controlled trial evaluating cabazitaxel versus docetaxel rechallenge for the treatment of metastatic Castrate Refractory Prostate Cancer, previously treated with docetaxel at inception of primary hormone therapy

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Feb 2017

At a glance

  • Drugs Cabazitaxel (Primary) ; Docetaxel
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Acronyms CANTATA
  • Most Recent Events

    • 04 Sep 2015 Accrual to date is 10% according to the United Kingdom Clinical Research Network record.
    • 12 Aug 2015 Accrual to date is 9% according to United Kingdom Clinical Research Network record.
    • 02 Jul 2015 Accrual to date is 8% according to United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top